Clinical Interventions in Aging (Jun 2023)
Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia
Abstract
Xueyao Li, Xiuzhen Tong Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of ChinaCorrespondence: Xiuzhen Tong, Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, 58 Second Zhongshan Road, Guangzhou, CPZN 510080, People’s Republic of China, Email [email protected]: There is overwhelming evidence indicating that the use of measurable residual disease (MRD) as a biomarker provides critical prognostic information and that MRD may have a role in directing postremission decisions. There are a variety of assays for MRD assessment, such as multiparameter flow cytometry and molecular assessment of MRD, which present different characteristics in patients older than 60 years of age. Due to multiple reasons related to age, the progress of older adult AML patients is rarely investigated, especially with respect to MRD. In this review, we will clarify the characteristics of different assays for assessing MRD, focusing on its role as a risk-stratification biomarker to predict prognostic information and its role in optimal postremission therapy among older adult AML patients. These characteristics also provide guidance regarding the potential to apply personalized medicine in older adult AML patients.Keywords: detection method, risk-stratification marker, postremission decisions, personalized medicine
